Introduction: The provision of safe, effective, cost-efficient perioperative inpatient acute pain
INTRODUCTION
The provision of safe, effective, cost-efficient perioperative inpatient acute pain management is an important concern among clinicians and administrators within healthcare institutions. Across a variety of surgeries, 20-55% of patients report at least moderate pain and up to 75% report severe pain during the immediate postoperative period, for a mean duration ranging from 1 to 8 days [1] [2] [3] [4] [5] . While readmission rates after a surgical discharge may be low, pain is a common reason for readmission among those returning to the hospital [6] . Additionally, untreated or inadequately treated acute postoperative pain can lead to chronic postsurgical pain [7] .
Furthermore, adverse drug events (ADEs) frequently are associated with postoperative pain management regimens. In general, ADEs have long been associated with increased mortality, longer hospital length of stay (LOS), and higher costs of hospitalization [8, 9] .
In 2000, the United States (US) Joint Commission on Accreditation of Healthcare Organizations (JCAHO), now referred to as the Joint Commission (JC), introduced pain management standards aimed at upholding a patient's right to effective assessment and treatment of pain from admission to discharge [10] .
However, the American Medical Association (AMA) has recommended that pain be removed as a ''fifth vital sign'' due to concerns about opioid over-prescribing, which critics contend could make it more difficult for those in pain to have their pain properly diagnosed and treated. Importantly, pain is a key input into the JC hospital accreditation score and the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
CAHPS
Ò Hospital Survey, and can impact overall hospital reimbursement by the government.
Acute Pain Management Using Opioids
In the US, intravenous (IV) opioid agonists such as morphine, hydromorphone, and fentanyl have traditionally been important analgesics in the treatment of pain in the immediate perioperative and critical care settings [11] [12] [13] .
In the first half of 2015, over 70% of surgical inpatients and outpatients in the US received opioid monotherapy for acute pain management [14] . Overreliance on opioid monotherapy in the inpatient healthcare setting raises health risks for patients and increases healthcare costs resulting from preventable adverse events. Opioid monotherapy can significantly increase a variety of opioid-related adverse drug events (ORADEs), most commonly nausea, vomiting, urinary retention, fatigue, pruritus, sleep impairment, dizziness, sedation, somnolence, and headache [15] . Less commonly, opioid monotherapy has been associated with ileus [16] , respiratory depression [17] , falls, and delirium, and in some extreme cases even death [18] . Numerous studies have demonstrated that managing these ORADEs is costly and they are associated with increased LOS [19] [20] [21] [22] .
Multimodal Analgesia
As an alternative to opioid monotherapy, multimodal analgesia (MMA) captures the effectiveness of individual agents in optimal dosages that maximize efficacy and attempts to minimize side effects from one analgesic [7] . This important concept employs the theory that agents with different mechanisms of analgesia, such as nonopioids (acetaminophen and nonsteroidal anti-inflammatory drugs
[NSAIDs]), opioids, local anesthetics, and anticonvulsants, may have synergistic effects in preventing or treating acute pain when used in combination [7] . The efficacy of multimodal analgesic regimens continues to improve, with opioid analgesics increasingly taking on the role of rescue analgesics for acute pain [23] .
Multimodal analgesia has been shown to reduce ADEs, LOS, readmissions, and costs associated with the use of opioids in multiple surgical populations [24, 25] . Intravenous acetaminophen (IV APAP) has been used as a [26, 27] . These findings are supported by a pharmacoeconomic review of IV APAP, which concluded the body of evidence shows the drug has the potential to improve outcomes and hospital efficiency [28] . Up to an estimated 7% of patients who receive prescription opioids following surgery end up using these medications long-term [29] [30] [31] [32] [33] , which can result in tolerance, dependence, and addiction [34] . It remains to be demonstrated whether reductions in postoperative opioid consumption associated with IV APAP reduce the risk of inappropriate extended use of opioids.
The goal of the current study was to estimate, through the use of statistical modeling, LOS, potential opioid-related complications, and costs for patients reducing opioid use and adding IV APAP for management of postoperative pain.
METHODS

Data Source
Data for this retrospective cohort study were derived from de-identified hospital billing and administrative data from the Advisory Board Company. This comprised 2,238,433 inpatient encounters across 297 hospitals from 1 January 2012 through 31 December 2014, with IV APAP identified in 271,394 encounters (12.1%).
Hospitals were not segmented by size to derive parameter estimates; however, only medium-sized hospitals (100-399 beds) [35] were selected to determine the number of cases used to model cost impact.
Drug utilization (see Table 1 for a list of opioid and non-opioid generic drug names for which data were collected in this study) was identified using hospital charge data for the encounter and is subject to the typical limitations of this approach, such as the potential for coding errors, and charges may not equate to amount of drug administered.
Patient Inclusion and Exclusion Criteria
Encounters for adults C18 years of age admitted for cardiovascular, colorectal, general, obstetrics and gynecology (OBGYN), orthopedics, or spine surgery based on the encounters' All Patient Refined Diagnosis-Related Group (APR-DRG) assignment (Table 2) were included. These six surgical categories represent high-volume procedures that were considered broadly applicable for the purpose of analysis.
Only data from acute care facilities with data available throughout the study period 
Definition of Complications
Potential ORADEs related to respiratory, gastrointestinal, central nervous system, urinary, and other events were defined using
International Classification of Disease-9th Revision-Clinical Modification (ICD-9-CM) codes [20] .
Modeling and Analytical Approach
There were two phases of modeling conducted in the study. The first phase was to determine parameter estimates, which describe the impact to LOS or complication rate based on drug utilization. The second was to employ those parameter estimates to model a specific treatment change and the downstream impact of that treatment change on LOS, complication rate, and costs. Because the data in this study were modeled, measures of central tendency and statistical tests of differences are not available.
The effects of reducing opioid use and adding IV APAP were estimated using Tables 3, 4) .
Details of the Regression Modeling
Hierarchical regressions were performed on random samples of n = 15,000 from the full sample (n = 2,238,443). Specifically, separate regressions were performed for each APR-DRG (17 total) and each of those regressions had a random sample of n = 15,000 from the given APR-DRG. These regressions were replicated with additional n = 15,000 samples to verify robustness of results and mitigate concerns about multiple comparisons. The levels used in hierarchical modeling were ''facility'' and ''attending physician,'' with individual hospitalizations within those two levels.
The first outcome of interest was LOS in days, which was modeled using hierarchical linear regression on its natural logarithm. The second outcome of interest was complications, which were grouped into six binary variables based on the ICD-9-coded categories (respiratory, urinary, central nervous system, GI, general, and related) and modeled each using hierarchical logistic regression.
As predictors, the following were included: ''emergency,'' ''urgent,'' ''elective,'' ''other''), and interactions between Elixhauser and each of (age, admission type, APR-DRG severity, and complications). Note that complications were predictors only in the LOS outcome models, and not in the complications outcome models. This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Overall
To put the impact of the LOS and complication rate reductions in context, the potential impact was modeled for a hypothetical (Table 5 ). For example, the calculated annual impact for a medium-sized facility (admissions 9 LOS reductions 9 HCUP 2013 $2383 cost per day of LOS) for the cardiovascular category overall (see first row in Table 5 ) is 276 9 1.01 9 2383 = $660,000
(rounded). Of note, the absence of P values and confidence intervals in Table 5 and Table 6 was due to derivation of cost savings estimates from a mix of nationally published reference costs and admission volumes, in addition to the parameter estimates from analysis of the observed data. Table 4 continued Calculated annual complication reduction cost savings (average medium-sized facility) = (cACR -cACRiv) 9 cCNT 9 cCST Sample calculation methods used to model complication results by reducing one level of opioid use and adding intravenous acetaminophen (IV APAP) are shown Table 6 Complication reductions and annual complications-related cost savings after dropping one level of opioid use and adding IV APAP (Table 6 ).
DISCUSSION
While opioid therapy is a fundamental component of postoperative pain management, the risk of ADEs and negative patient outcomes pose significant safety concerns [36] . Increasingly, a multimodal approach to pain management is being used as a way to decrease postoperative opioid reliance but still provide optimal pain control [37] .
Because of reduced opioid doses used, this new approach to pain management may decrease the risk of ORADEs [24, 38] and associated health care costs [25, 38] . Recent pain guidelines for critically ill patients suggest this approach to avoid ADEs [12] . Since hospitals and outpatient clinics strive to provide care in an efficient and cost-effective manner to survive in the current budget-conscious healthcare climate, a major issue is providing balanced pain management while using the lowest effective dose of opioids. In particular, HCAHPS scores are tied to reimbursement, and two questions relate to pain management [39] . 
Limitations of the Study
Although the authors consider the results of the current study to be valid, certain methodological procedures were not feasible to perform that would have enhanced rigor. Specifically, propensity scores or any other kind of pre-analysis matching data treatments were not used. In addition, study constraints precluded matching.
Opioid and non-opioid drug doses were categorized according to charge data, which has limited precision in regards to quantity/doses of drug a patient received.
Therefore, ordinal bucketed categories were used instead of continuous measures.
Estimated dosing was based on quantities charged, which is not a consistent representation of actual dosing. Out-of-range quantities were adjusted based on assumptions of use of mg/mL as charge quantities rather than dose quantity. Use of IV APAP was coded as a binary yes/no.
Due to study constraints, as with opioid and non-opioid cases, a finer measure could not be used.
As listed in the regression details, some interactions were included whereas others were not. Optimally, the many dozens of different kinds of interactions between all our variables would have been examined, but, due to the large number of models involved in this study (17 APR-DRGs across 2 outcomes equals 34 models of interest), it was unfeasible to produce highly customized models for each case.
The limitations noted here raise the question whether all of the different modeling decisions made put the analysis at risk of implicit multiple comparisons problems [53, 54] . While the data were not modeled in all of the variations desired, an attempt was made to mitigate the multiple concern by replicating regression results with new samples, as mentioned above. The replications performed also confirmed the findings of this analysis.
Future Research Considerations
Although the current study collected data on non-opioid pain medications in addition to IV APAP, analysis of these data was beyond the scope of the current study and may warrant future analysis and reporting. Additional work to better understand the impact of opioid reduction on percutaneous cardiovascular procedures without AMI may be of interest.
Also, analysis of specific MMA approaches to identify the APR-DRGs for which they appear to provide the most benefit with respect to decreased LOS, opioid-related complication rates, and overall hospital costs may be warranted.
CONCLUSIONS
Prevention of ORADES rather than treatment of
ADEs is a more effective strategy for hospitals, given the large economic burden and negative impact on patient outcomes associated with these events. A multimodal approach is a growing strategy to minimize the frequency of 
